循環器の名門University of Wisconsinで初登録。
以下の記事要約では、Phase3とあるが、正しくはPhase3b。他医療機関でも進行中の商業化申請に向けた250人の最終治験。
BCDA announced that the University of Wisconsin enrolled its first patient in the Phase 3 CardiAMP HF II trial, which tests the safety and efficacy of CardiAMP autologous cell therapy for ischemic heart failure. The 250-patient study uses a composite primary endpoint and improved cell and delivery methods, with this enrollment expected to enhance the trial’s strength and reach.
循環器の名門University of Wisconsinで初登録。
以下の記事要約では、Phase3とあるが、正しくはPhase3b。他医療機関でも進行中の商業化申請に向けた250人の最終治験。
BCDA announced that the University of Wisconsin enrolled its first patient in the Phase 3 CardiAMP HF II trial, which tests the safety and efficacy of CardiAMP autologous cell therapy for ischemic heart failure. The 250-patient study uses a composite primary endpoint and improved cell and delivery methods, with this enrollment expected to enhance the trial’s strength and reach.
投資の参考になりましたか？